Please assess the completion status of the following clinical trial:

Trial Title: Ketamine for Depression and Suicide Risk

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current psychiatric hospital inpatient at Mayo Clinic at time of initiation of treatment.~* Ability to provide informed consent~* Male/Female~* Age 18-65 yrs.~* Major Depressive Disorder or Bipolar Disorder I or Bipolar Disorder II with Patient Health Questionnaire-9 (PHQ 9) score ≥15 at hospital assessment~* Treatment resistant depression (TRD) as defined by at least two previous antidepressant or mood stabilizing treatments for depression in adequate dose for 8 weeks~* Patient reported overall suicide risk score ≥3 on the Suicide Status Form (SSF II-R) or score of ≥1on Item 9 of PHQ-9 (all at admission assessment)~* Ability to pass comprehension assessment test related to effects of ketamine and trial objectives and criteria~* Voluntary admission~Exclusion Criteria:~* Diagnosis of schizophrenia, schizoaffective disorder, or active psychosis~* Index episode of depression greater than 2 years~* Ongoing prescription of ≥4 mg lorazepam equivalents total daily or a.m. dosing of any benzodiazepine at time of assessment~* Currently undergoing electroconvulsive therapy, deep brain stimulation or transcranial magnetic stimulation as acute series or for maintenance~* Any active or unstable medical condition as judged by principal investigator~* Previous use or abuse of methamphetamine, cocaine, stimulants (prescribed and illicit) within past 12 months~* Any current abuse or dependence of alcohol or drugs (except nicotine) and abuse or dependence of drugs and alcohol only in full remission (\> 1 month, \< 12 months). Patients will be allowed to enroll if their drug and alcohol abuse / dependence is in full (complete, not partial) sustained (\> 1 year) remission.~* History of traumatic brain injury~* Developmental delay and intellectual disorder~* Encephalopathy (clinical diagnosis within prior 12 months of delirium)~* Cognitive disorder (mild and major)~* Previous participation in earlier Ketamine trial~* Pregnancy~* Prisoners~* Involuntarily hospitalized

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine infusion (Type: EXPERIMENTAL): This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).